Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) on Monday reported promising results from its Phase 2/3 COVA study of oral BIO101 (20-hydroxyecdysone) in the treatment of severe COVID-19 in hospitalised adults.

The findings were presented at the World Congress on Infectious Diseases in Paris, France.

Biophytis reported a statistically significant 43.8% reduction in the risk of early respiratory failure or death, along with a 44.6% reduction in the 90-day death rate. These positive findings come amid rising COVID-19 cases.